CTLA4 and cancer: Our integrated methylome-transcriptome pathway analysis showed enrichment of the CTLA4 signaling and PD-1 and PD-L1 cancer immunotherapy pathways coupled with an increase in antigen presentation and major histocompatibility complex (MHC) class I after sequential azacitidine and carboplatin treatment of HGSOC cell lines.